智通财经APP讯,佰金生命科学(01466)发布公告,集团预期截至2025年9月30日止六个月将取得纯利约250万港元,而截至2024年9月30日止六个月则取得亏损约为190万港元。集团截至2025年9月30日止六个月的财务业绩增长乃主要由于可换股债券公平值变动收益及抵销毛利减少后所致。
智通财经APP讯,佰金生命科学(01466)发布公告,集团预期截至2025年9月30日止六个月将取得纯利约250万港元,而截至2024年9月30日止六个月则取得亏损约为190万港元。集团截至2025年9月30日止六个月的财务业绩增长乃主要由于可换股债券公平值变动收益及抵销毛利减少后所致。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.